Mateo J, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol. 2019;75:285-293.
Patil T, et al. Complications of androgen deprivation therapy in men with prostate cancer. Oncology (Williston Park). 2018;32:470-474.
Smith MR, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918-2925.
Wirth MP, et al. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program. Front Radiat Ther Oncol. 2008;41:39-48.
Dorff TB, et al. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol. 2013;24:31-38.
Mottet N, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243-262.
Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378:1408-1418.
Smith MR, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150-158.
Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380:1235-1246.
Fizazi K, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040-1049.
Hussain M, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465-2474.
Sternberg CN, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197-2206.
Crawford ED, et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology. 2014;83:664-669.
Apalutamide Product Information. European Medicines Agency (EMA). Published March 19, 2019. Updated April 12, 2021.
Darolutamide Product Information. European Medicines Agency (EMA). Published April 1, 2020. Updated November 13, 2021.
Enzalutamide Product Information. European Medicines Agency (EMA). Published July 2, 2013. Updated June 23, 2021.
Ost P, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36:446-453.
Smith MR, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013;31:3800-3806.
Cornford P, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263-282.
Oudard S, et al. Health-related quality of life at the spartan final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy. Eur Urol Focus. 2021. doi:10.1016/j.euf.2021.08.005 [Epub ahead of print]
Tombal B, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:556-569.
Smith MR, et al. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021;154:138-146.
Apalutamide [prescribing information]. Approved 2018. Revised November 2020.
Enzalutamide [prescribing information]. Approved 2019. Revised October 2020.
Darolutamide [prescribing information]. Approved 2019. Revised July 2019.
Shore N, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019;14:527-539.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Heather Payne, MBBS, FRCP, FRCR

Consultant in Clinical Oncology
University College Hospital
London, United Kingdom

Disclosures

Disclosure: Heather Payne, MBBS, FRCP, FRCR, has the following relevant financial relationships:
Advisor or consultant for: AAA; AstraZeneca; Astellas; Bayer; Ferring; Janssen; Novartis
Speaker or a member of a speakers bureau for: AAA; AstraZeneca; Astellas; Bayer; Ferring; Janssen; Novartis
Grants for clinical research from: Astellas; Janssen

Editors

Deborah Grainger, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Grainger, PhD, has disclosed no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, WebMD Global, LLC

Disclosures

Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

The Nonmetastatic Castration-Resistant Prostate Cancer Enigma: Who Are These Patients, and Why Is it Important to Identify and Treat?

Authors: Heather Payne, MBBS, FRCP, FRCR
CPD Released: 12/8/2021; Reviewed and Renewed: 11/8/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/8/2022, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of oncologists, urologists, pathologists, primary care physicians, and other members of the oncology care team treating patients with prostate cancer in the United Kingdom.

The goal of this activity is to define the need to identify patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and optimal approaches for treatment of this group of patients.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Identification of patients with nmCRPC
- Importance of treatment for nmCRPC

Disclosures

Faculty

Heather Payne, MBBS, FRCP, FRCR

Consultant in Clinical Oncology
University College Hospital
London, United Kingdom

Disclosures

Disclosure: Heather Payne, MBBS, FRCP, FRCR, has the following relevant financial relationships:
Advisor or consultant for: AAA; AstraZeneca; Astellas; Bayer; Ferring; Janssen; Novartis
Speaker or a member of a speakers bureau for: AAA; AstraZeneca; Astellas; Bayer; Ferring; Janssen; Novartis
Grants for clinical research from: Astellas; Janssen

Editors

Deborah Grainger, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Deborah Grainger, PhD, has disclosed no relevant financial relationships.

Tristin Abair, PhD

Senior Medical Writer, WebMD Global, LLC

Disclosures

Disclosure: Tristin Abair, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

The Nonmetastatic Castration-Resistant Prostate Cancer Enigma: Who Are These Patients, and Why Is it Important to Identify and Treat?

Authors: Heather Payne, MBBS, FRCP, FRCRFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 12/8/2021; Reviewed and Renewed: 11/8/2021

Valid for credit through: 12/8/2022, 11:59 PM EST

processing....

Assessment Survey

Before you begin, please answer the questions in this brief survey.

Page 1 of 4

CPD Information

Print
Like Tweet

References

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Heather Payne, MBBS, FRCP, FRCR

Editors

Deborah Grainger, PhD

Tristin Abair, PhD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

The Nonmetastatic Castration-Resistant Prostate Cancer Enigma: Who Are These Patients, and Why Is it Important to Identify and Treat?

Target Audience and Goal Statement

Disclosures

Faculty

Heather Payne, MBBS, FRCP, FRCR

Editors

Deborah Grainger, PhD

Tristin Abair, PhD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

The Nonmetastatic Castration-Resistant Prostate Cancer Enigma: Who Are These Patients, and Why Is it Important to Identify and Treat?

Assessment Survey